Status of Public Health Impact and Health Economic Analyses for Vaccines 7-8 May 2013 WHO, Geneva, Switzerland

Final list of participants

Robert F. Breiman, Director, Emory Global Health Institute, Emory University, 1599 Clifton Road, Suite 6.101, Atlanta, GA 30322, United States of America

Philip Eckhoff, Research Scientist, Intellectual Ventures Lab,1555 132nd Avenue, Building 4, Bellevue, WA 98005, United States of America

Katya Galactionova, Health Systems Research Unit, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland

Peter W. Gething, MRC Career Development Fellow, Department of Zoology, , Spatial Ecology and Epidemiology Group, South Parks Road, Oxford OX1 3PS, United Kingdom of Great Britain & Northern Ireland

Azra Ghani, Head, Infectious Disease Epidemiology, , 15 Prince's Gardens, London SW7 1NA, United Kingdom of Great Britain & Northern Ireland

Jamie T. Griffin, MRC Research Fellow, Imperial College London, 15 Prince's Gardens, London SW7 1NA, United Kingdom of Great Britain & Northern Ireland

Mark Jit, Mathematical Modeller, Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, London, NW9 5HT, United Kingdom of Great Britain & Northern Ireland

Paul Milligan, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom of Great Britain & Northern Ireland

Melissa Penny, Health Systems Research Unit, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland

Maarten Postma, Groningen Research Institute of Pharmacy (GRIP), University of Groningen Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands

Peter Smith, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom of Great Britain & Northern Ireland

Thomas Smith, Head of Biostatistics and Computational Sciences, Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Socinstrasse 57, CH-4051, Basel, Switzerland

Rick Steketee, Science Director, Malaria Control and Evaluation Partnership in Africa (MACEPA), Seattle, WA 98109, United States of America (via teleconference)

Neff Walker, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205, United States of America (via teleconference)

../2

Edward Wenger, Research Scientist, Intellectual Ventures Lab,1555 132nd Avenue, Building 4, Bellevue, WA 98005, United States of America

Lisa White, Head, Mathematical and Economic Modelling of Diseases, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

OBSERVERS

Standaert Baudouin, Director Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 1300 Wavre, Belgium

Carla Botting, Head RTS, S Program and Director, Product Development and Access, Malaria Vaccine Initiative (MVI), Program for Appropriate Technology in Health, Bethesda, MD 20817, United States of America

Hope Johnson, Head, Programme Outcomes and Impact, Monitoring and Evaluation Policy & Performance, GAVI Alliance Secretariat, c/o UNICEF, Palais des Nations, Genève 10 CH- 1211, Switzerland

Farzana Muhib, Project Manager, Product Development, Malaria Vaccine Initiative (MVI), Program for Appropriate Technology in Health, Bethesda, MD 20817, United States of America

Christophe Sauboin, Senior Manager, Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 1300 Wavre, Belgium

Thierry Van Effelterre, Senior Manager, Epidemiology - Mathematical Modelling, GlaxoSmithKline Biologicals, Rixensart 1330, Belgium

WHO SECRETARIAT

Raymond Hutubessy, Economist, Initiative for Vaccine Research, Implementation Research, World Health Organization, Switzerland

Vasee Moorthy, Technical Officer, HIV Vaccine Initiative, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland